Additional file 1 of Identification of ACBD3 as a new molecular biomarker in pan-cancers through bioinformatic analysis: a preclinical study
Creators: name: Ma, Xinyue
name: Huang, Shu
name: Shi, Huiqin
name: Luo, Rui
name: Luo, Bei
name: Tan, Zhenju
name: Shi, Lei
name: Zhang, Wei
name: Yang, Weixing
name: Zhong, Xiaolin
name: Lü, Muhan
name: Chen, Xia
name: Tang, Xiaowei
Publisher: name: figshare
Year: 2024
Subjects: subject: Biophysics
subject: Biochemistry
subject: Genetics
subject: FOS: Biological sciences
subject: Molecular Biology
subject: Immunology
subject: FOS: Clinical medicine
subject: Biological Sciences not elsewhere classified
subject: Developmental Biology
subject: Cancer

description: Additional file 1: Figure S1 The expression level of ACBD3. A In normal tissues, ACBD3 expressed highly in cerebral cortex, hippocampus, duodenum, small intestine, colon, gallbladder, pancreas, prostate, placenta, appendix, and bone marrow. Moreover, ACBD3 expressed lowly in oral mucosa, liver, ovary, soft tissue, and adipose tissue; B In tumor cell lines, The expression of ACBD3 ranks high in breast cancer, kidney cancer, and myeloma in tumor cell lines; C, D Intracellular ACBD3 is mainly distributed in Golgi; E ACBD3 expressed high in SKCM, BRCA, GBM, KIRC, LGG, and THCA in Cancer Cell Line Encyclopedia (CCLE) database. Small cell lung cancer (SCLC), colon and rectal cancer (COADREAD), large b-cell lymphoma (DLBC), sarcoma (SARC), multiple myeloma (MM), acute myeloid leukemia (LAML), skin cutaneous melanoma (SKCM), breast cancer (BRCA), liver hepatocellular carcinoma (LIHC), mesothelioma (MESO), ovarian cancer (OV), esophageal cancer (ESCA), endometrioid cancer (UCEC), glioblastoma multiforme (GBM), pancreatic adenocarcinoma (PAAD), neuroblastoma (NB), lung adenocarcinoma (LUAD), stomach adenocarcinoma (STAD), kidney clear cell carcinoma (KIRC), non-small cell lung carcinoma (NSC), acute lymphoeytic leukemia (ALL), lung squamous cell carcinoma (LUSC), brain lower grade glioma (LGG), head and neck cancer (HNSC), thyroid cancer (THCA), chronic myelocytic leukemia (LCML), Human medulloblastoma cells (MB), prostate cancer (PRAD), cervical cancer (CESC), chronic lymphocytic leukemia (CLL). Figure S2 Correlation between immune infiltrates and ACBD3 expression in different tumors. head and neck cancer (HNSC), bladder cancer (BLCA), colon cancer (COAD), thyroid cancer (THCA), kidney clear cell carcinoma (KIRC). A The expression of ACBD3 was actively correlated with the cancer-associated fibroblast (CAF) infiltration for HNSC. B The expression of ACBD3 was positively related to neutrophil infiltration for BLCA, COAD, and THCA. C ACBD3 expression was positively related to endothelial cell infiltration for COAD, HNSC, and KIRC. Figure S3 Kaplan–Meier plots ([Overall Survival (OS)]) for ACBD3 expression in pan-cancers. A Pancreatic For pancreatic adenocarcinoma (PAAD), there was no statistically significant relationship between ACBD3 expression and prognosis. B For Glioma (GBMLGG), the OS prognosis was negatively related to ACBD3 expression, HR = 2.30, 95% CI: 1.19–4.43, p = 0.013. C For adrenocortical carcinoma (ACC), there was no statistically significant relationship between ACBD3 expression and prognosis.